• Kiora Pharmaceuticals swung to a third-quarter 2026 net loss of $1.75 million from year-earlier net income of $26,806.
• Collaboration revenue reached $1 million from the KIO-301 agreement with CKD, versus no revenue a year earlier.
• Quarter-end cash and short-term investments totaled approximately $16.3 million, with $2.2 million in collaboration, tax and other receivables.
• It in-licensed KIO-401 rights outside Asia and plans a multinational Phase 3 registration trial for central retinal artery occlusion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611120700NEWSFILECNPR____20261112_323497_1) on November 12, 2026, and is solely responsible for the information contained therein.